TY - JOUR
T1 - Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Health-Related Quality of Life in Sepsis
AU - Grossestreuer, Anne V.
AU - Moskowitz, Ari
AU - Andersen, Lars W.
AU - Holmberg, Mathias J.
AU - Konacki, Varun
AU - Berg, Katherine M.
AU - Chase, Maureen
AU - Cocchi, Michael N.
AU - Donnino, Michael W.
N1 - Publisher Copyright:
© 2020 The Authors. Published by Wolters Kluwer Health, Inc.
PY - 2020/11/23
Y1 - 2020/11/23
N2 - Objectives: Patients who experience sepsis often have long-term effects that may impact health-related quality of life. This study aimed to investigate whether the combination of ascorbic acid, corticosteroids, and thiamine compared with placebo improves health-related quality of life in patients with septic shock. Design: Secondary analysis of the Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis randomized controlled trial (NCT03389555). Setting: Thirteen tertiary-care hospitals in the United States. Patients: Patients who were enrolled in Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis, survived to 90 days post enrollment and were able to be contacted by telephone. Interventions: Patients were randomly assigned to parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days or placebo. Measurements and Main Results: One hundred seventeen patients (59%) survived to 90 days and were administered the Short Form 36 questionnaire; of these, 72 (62%) completed the Short Form 36 (38 [53%] in the intervention group, 34 [47%] in placebo). Sixty-six (92%) completed all survey questions (36 [95%] in the intervention group, 30 [88%] in placebo). There was no significant difference in overall Short Form 36 score between intervention and placebo group (median score: 39.4 [interquartile range, 31.2-45.4] vs 43.2 [37.0-46.7], respectively, p = 0.18). We found no statistically significant difference between the two groups in any of the other health-related quality of life domains used. Conclusions: We found no difference in the health-related quality of life in patients with septic shock treated with a combination of ascorbic acid, corticosteroids, and thiamine compared to placebo.
AB - Objectives: Patients who experience sepsis often have long-term effects that may impact health-related quality of life. This study aimed to investigate whether the combination of ascorbic acid, corticosteroids, and thiamine compared with placebo improves health-related quality of life in patients with septic shock. Design: Secondary analysis of the Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis randomized controlled trial (NCT03389555). Setting: Thirteen tertiary-care hospitals in the United States. Patients: Patients who were enrolled in Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis, survived to 90 days post enrollment and were able to be contacted by telephone. Interventions: Patients were randomly assigned to parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days or placebo. Measurements and Main Results: One hundred seventeen patients (59%) survived to 90 days and were administered the Short Form 36 questionnaire; of these, 72 (62%) completed the Short Form 36 (38 [53%] in the intervention group, 34 [47%] in placebo). Sixty-six (92%) completed all survey questions (36 [95%] in the intervention group, 30 [88%] in placebo). There was no significant difference in overall Short Form 36 score between intervention and placebo group (median score: 39.4 [interquartile range, 31.2-45.4] vs 43.2 [37.0-46.7], respectively, p = 0.18). We found no statistically significant difference between the two groups in any of the other health-related quality of life domains used. Conclusions: We found no difference in the health-related quality of life in patients with septic shock treated with a combination of ascorbic acid, corticosteroids, and thiamine compared to placebo.
KW - ascorbic acid
KW - corticosteroids
KW - quality of life
KW - sepsis
KW - thiamine
UR - http://www.scopus.com/inward/record.url?scp=85133713907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133713907&partnerID=8YFLogxK
U2 - 10.1097/CCE.0000000000000270
DO - 10.1097/CCE.0000000000000270
M3 - Article
AN - SCOPUS:85133713907
SN - 2639-8028
VL - 2
SP - E0270
JO - Critical Care Explorations
JF - Critical Care Explorations
IS - 12
ER -